Revvity, Inc. Monthly Stock Report - January 2026

Company Overview

Revvity, Inc. (NYSE: RVTY), headquartered in Waltham, Massachusetts, is a prominent player within the Healthcare sector, specializing in the Diagnostics & Research industry. Established in 1937 and formerly known as PerkinElmer, Inc., Revvity focuses on offering a diverse array of health science solutions, including instruments, reagents, software, and DNA sequencing technologies. These innovations play a pivotal role in the early detection of genetic disorders and infectious diseases.

Revvity caters to a broad range of clients, such as pharmaceutical and biotechnology firms, laboratories, academic institutions, public health authorities, and healthcare organizations. With a commitment to advancing genomic workflows for oncology, immunodiagnostics, and drug discovery, the company sits strategically positioned in a vital and rapidly growing industry. As of January 2026, Revvity's strong financial performance and innovative product offerings contribute to its compelling investment proposition, currently backed by a favorable 'buy' recommendation.

52-Week Price Performance Analysis

52-Week Price Performance Chart

Analyzing Revvity's stock performance over the past year reveals significant challenges and potential opportunities. The stock commenced the year at approximately $130 but encountered a persistent downward trend, ultimately reaching a 52-week low of $81.36 in September. The bears have been active, with the share price forming a pattern of lower highs and lower lows, establishing a clear downtrend.

As of the start of January 2026, Revvity's stock is trading at $97.49, slightly above its 50-day moving average of $97.077. This may indicate that the stock is stabilizing after facing challenges. Key resistance is noted around the $110 level; this is a psychological barrier with previous highs indicating difficulty for the price to generate upward momentum. Conversely, the support level is identified near $85, where the stock has shown resilience and bounced back on multiple occasions.

Recent chart activity suggests a potential reversal in momentum since the price broke above the blue moving average in late October. However, the price has recently stabilized around $96.75, approximately 14.59% lower than its annual high and exhibiting a sideways pattern just below the critical $100 resistance. Traders should closely monitor for a decisive break above or below these levels to predict the stock's next directional move.

Financial Performance and Metrics

Revvity's financial performance strengthens its investment case, with total revenues reported at $2.81 billion. This figure signifies strong operational capabilities and market demand for its offerings. In the third quarter of 2025, the company reported an adjusted earnings per share (EPS) of $1.18, beating analyst expectations of $1.14, although quarterly revenues fell short at approximately $699 million compared to the consensus estimate of $700.5 million.

Despite the revenue miss, Revvity raised its full-year EPS guidance to a range of $4.90 to $5.00 and announced an impressive $1 billion share repurchase program over the next two years, indicating strong confidence in its future performance. The company's EBITDA stands at $824 million, highlighting its potential for profitability and operational efficiency. Currently, the stock trades at a price-to-earnings (P/E) ratio in the mid-teens, suggesting it is reasonably valued compared to its peers in the diagnostics space.

Moreover, Revvity has maintained a commendable history of dividend payments, recently declaring a quarterly dividend of $0.07 per share, marking its 55th consecutive year of such payments. This reflects the company's commitment to returning value to shareholders, further enhancing its attractiveness as an investment.

Recent News and Developments

In recent weeks, Revvity has made headlines with its financial announcements and strategic initiatives. The company's decision to initiate a $1 billion share repurchase program over two years highlights management's confidence in its future growth prospects and aims to enhance shareholder value. As of the record date of January 16, 2026, shareholders stand to benefit from the upcoming dividend payment.

Further adding to discussions around Revvity are mixed market sentiments. Goldman Sachs initiated coverage with a "Neutral" rating, whereas Bernstein has lowered its price target on account of challenges in the Chinese immunodiagnostics market, which represents around 6% of the company's total revenue.

Despite a 52-week low of $85.01 reached in late 2025, investor sentiment seems cautiously optimistic, considering the overall financial landscape and future guidance. The stock's price movement and performance will be critical to analyze as global market conditions evolve, particularly regarding the ongoing trends within the healthcare diagnostics field.

Market Sentiment and Analyst Recommendations

Market sentiment surrounding Revvity, Inc. appears mixed but cautiously optimistic. The current stock price at $97.49 positions it favorably against analysts' price targets, which project a target high price of $135.00, indicating a significant upside potential of approximately 38.4%. The mean target price of around $114.375 and median target at $115 further reinforce a bullish outlook for the stock.

A group of 16 analysts provides a consensus recommendation categorizing Revvity within the 'buy' category, with an overall mean recommendation rating of 2.0. However, the stock is met with some caution as reflected by the neutral coverage from Goldman Sachs and the downward adjustment from Bernstein, which points to potential headwinds that investors should be aware of.

In conclusion, while the short-term outlook for Revvity may appear more optimistic with signs of potential bullish momentum, investors should remain aware of the underlying bearish trends and the challenges posed by market fluctuations. Overall, Revvity, Inc.'s strong operational performance, combined with an enticing market position and revenue potential, creates a compelling investment opportunity for those willing to capitalize on both the risks and rewards within the evolving healthcare diagnostics landscape.